NASDAQ:PRQR ProQR Therapeutics (PRQR) Stock Price, News & Analysis $1.43 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.51 +0.08 (+5.38%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ProQR Therapeutics Stock (NASDAQ:PRQR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProQR Therapeutics alerts:Sign Up Key Stats Today's Range$1.40▼$1.5450-Day Range$1.37▼$1.9952-Week Range$1.33▼$3.10Volume1.25 million shsAverage Volume712,581 shsMarket Capitalization$150.66 millionP/E RatioN/ADividend YieldN/APrice Target$7.25Consensus RatingModerate Buy Company Overview ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa. Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives. Its dual-platform approach—combining site-directed RNA editing with direct RNA therapies—underpins efforts to address a range of monogenic disorders affecting the eye, skin and other organ systems. By focusing on mRNA modulation rather than permanent DNA edits, ProQR seeks to deliver treatments that may offer reversibility and a favorable safety profile. ProQR has advanced multiple programs into early- and mid-stage clinical trials in North America and Europe, collaborating with leading academic institutions and industry partners. Multidisciplinary teams in molecular biology, translational research, and clinical development drive the company’s efforts to demonstrate proof of concept and navigate regulatory pathways. Ongoing studies aim to establish dosing, safety and efficacy in patient populations with high unmet medical needs. Led by CEO Daniel de Boer and supported by a management team with extensive expertise in biotechnology and ophthalmology, ProQR continues to refine its platforms and expand its pipeline. The company actively pursues strategic partnerships and funding opportunities to accelerate its mission of transforming lives through innovative RNA medicines for rare genetic disorders.AI Generated. May Contain Errors. Read More ProQR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScorePRQR MarketRank™: ProQR Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 258th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingProQR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialProQR Therapeutics has a consensus price target of $7.25, representing about 407.0% upside from its current price of $1.43.Amount of Analyst CoverageProQR Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about ProQR Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ProQR Therapeutics are expected to decrease in the coming year, from ($0.57) to ($0.67) per share.Price to Book Value per Share RatioProQR Therapeutics has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ProQR Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of ProQR Therapeutics has been sold short.Short Interest Ratio / Days to CoverProQR Therapeutics has a short interest ratio ("days to cover") of 0.92, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ProQR Therapeutics has recently decreased by 33.01%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProQR Therapeutics does not currently pay a dividend.Dividend GrowthProQR Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentProQR Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ProQR Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for PRQR on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat Follows4 people have added ProQR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProQR Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders8.40% of the stock of ProQR Therapeutics is held by insiders.Percentage Held by Institutions32.65% of the stock of ProQR Therapeutics is held by institutions.Read more about ProQR Therapeutics' insider trading history. Receive PRQR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProQR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRQR Stock News HeadlinesProQR Posts Wider Q1 2026 Loss but Maintains Strong Cash PositionMay 17 at 1:13 PM | theglobeandmail.comWall Street Zen Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Strong SellMay 16, 2026 | americanbankingnews.comThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, supplier Broadcom gained 15,000%. The pattern is clear: suppliers often dwarf the headline stock. One little-known company has shipped over 5 billion chips to SpaceX - a figure expected to reach 10 billion by 2027. SpaceX calls them 'instrumental to Starlink's success.' With the IPO expected in June, you can get the name, ticker, and a full year of tech research for just $19 - 85% off.May 20 at 1:00 AM | Weiss Ratings (Ad)ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%May 14, 2026 | finance.yahoo.comProQR Announces First Quarter 2026 Operating and Financial ResultsMay 12, 2026 | globenewswire.comProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing PlatformMay 11, 2026 | globenewswire.comProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026May 4, 2026 | globenewswire.comProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of DirectorsApril 30, 2026 | globenewswire.comSee More Headlines PRQR Stock Analysis - Frequently Asked Questions How have PRQR shares performed this year? ProQR Therapeutics' stock was trading at $2.02 on January 1st, 2026. Since then, PRQR stock has decreased by 29.2% and is now trading at $1.43. How were ProQR Therapeutics' earnings last quarter? ProQR Therapeutics N.V. (NASDAQ:PRQR) announced its quarterly earnings data on Tuesday, May, 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, hitting the consensus estimate of ($0.15). The biopharmaceutical company had revenue of $2.35 million for the quarter, compared to analysts' expectations of $5.19 million. ProQR Therapeutics had a negative net margin of 331.33% and a negative trailing twelve-month return on equity of 84.87%. When did ProQR Therapeutics IPO? ProQR Therapeutics (PRQR) raised $90 million in an initial public offering (IPO) on Thursday, September 18th 2014. The company issued 7,500,000 shares at a price of $11.00-$13.00 per share. Who are ProQR Therapeutics' major shareholders? Top institutional investors of ProQR Therapeutics include Walleye Capital LLC (0.58%), Bank of America Corp DE (0.18%), RFG Advisory LLC (0.02%) and Group One Trading LLC (0.02%). How do I buy shares of ProQR Therapeutics? Shares of PRQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProQR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProQR Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE). Company Calendar Last Earnings5/12/2026Today5/20/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PRQR's financial health is in the Red zone, according to TradeSmith. PRQR has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRQR CIK1612940 Webwww.proqr.com Phone(188) 166-7000FaxN/AEmployees180Year Founded2012Price Target and Rating Average Price Target for ProQR Therapeutics$7.25 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+407.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$47.73 million Net Margins-331.33% Pretax Margin-339.53% Return on Equity-84.87% Return on Assets-37.78% Debt Debt-to-Equity RatioN/A Current Ratio2.48 Quick Ratio2.48 Sales & Book Value Annual Sales$17.99 million Price / Sales8.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book3.40Miscellaneous Outstanding Shares105,360,000Free Float96,511,000Market Cap$150.66 million OptionableOptionable Beta0.08 Social Links The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:PRQR) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThis same-day trade is getting a lot of attentionZero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe filing was one thing. June 1 is another.The SpaceX filing got attention - but according to macroeconomic strategist Dr. Mark Skousen of The Oxford Clu...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
